Gene-Disorder Association · Article
First reported
1950
Supporting publications
13
Approved treatment annotated
Association Review
In brief The association between CAPN10 (Calpain 10) and Polycystic Ovary Syndrome is supported by expert-curated evidence, supported by a single expert-curated source.
Sources
1
Clinical variants
1
Symptoms
1
Compounds
1
Trials
186 of 1,949 via CAPN10 compounds
Publications
13
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Polycystic Ovary Syndrome
The disorder 8 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
ClinVar and variant evidence
Genetic basis 1 clinical variant
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access 06
Interventions
Therapeutics 1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 07
Human studies
Clinical trials 1,949 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 13 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access 09
Provenance
References & sources 14 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
